Good
Mostly Aligned
Patient Risk:
Low
Summary
Most extracted claims about pediatric minimum age/weight thresholds are supported by the provided label text in Section 8.4. One claim about off-label specialist use is not addressed in the provided label content and is therefore unsupported/absent-from-label.
Category Scores
Accurate Statements
For pediatric plaque psoriasis, Cosentyx has an approved pediatric age range in the prescribing information that specifies a minimum age for that indication.
Section 8.4: pediatric plaque psoriasis established for ages 6 years and older.
Cosentyx can be used in children only for indications where it is specifically approved for pediatric use.
Section 8.4: safety/effectiveness established only for specified pediatric indications/age (and some weight) ranges; states lack of establishment below those ranges.
Pediatric approvals for Cosentyx include defined age limits in the prescribing information.
Section 8.4: multiple pediatric indications list specific minimum ages (and some weight thresholds) and explicitly state lack of establishment below those thresholds.
If a patient is below the approved minimum age for a given Cosentyx indication, clinicians typically cannot use it according to the labeled indication.
Section 8.4: for each pediatric indication, labeling states safety/effectiveness have not been established below the specified age (and/or weight) threshold.
Unsupported Statements
Off-label use of Cosentyx may occur in rare circumstances under specialist care, but it is not the same as an approved age limit.
The provided label text does not discuss off-label prescribing, specialist circumstances, or the concept of 'rare circumstances' for off-label use.
Contradictions
Important Omissions
The first claim mentions other disease entities (including ankylosing spondylitis and non-radiographic axial spondyloarthritis) and implies age cutoffs for these uses; however, the provided label excerpt (Section 8.4) only explicitly provides pediatric age cutoffs for pediatric plaque psoriasis, juvenile psoriatic arthritis, juvenile ankylosing spondylitis, axial juvenile spondyloarthritis (not established), enthesitis-related arthritis, and hidradenitis suppurativa. The excerpt does not provide pediatric age cutoffs for ankylosing spondylitis or non-radiographic axial spondyloarthritis as adult indications translated into pediatric age thresholds.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
All safety-relevant points evaluated rely on labeled statements that safety/effectiveness have not been established below specified pediatric ages (and some weight thresholds). The unsupported off-label specialist-use statement is not directly reflected in label text; the potential impact is limited because it does not provide an actionable dosing instruction.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
One off-label/specialist-use statement is not supported by the provided label content, and the first claim overreaches by suggesting pediatric age cutoffs for ankylosing spondylitis and non-radiographic axial spondyloarthritis beyond what is shown in the provided Section 8.4 excerpt.
Suggested Improvement
Limit the description of pediatric age cutoffs to the pediatric indications explicitly covered in the provided Section 8.4 excerpt, and remove or rephrase the off-label specialist-use statement since it is absent from the label text provided.